Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesQuince Therapeutics, Inc.

Quince Therapeutics, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
33.775 USD 2.77 ( 8.95%)
Last update at 2026-11-09T14:30:00Z
VOLUME
125200
Market Cap
36.30M

Momentum Score

…

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
29.50
Low
35.12
High
52 Week Price Range
0.83
Low
1.70
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
31.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.16
ROE
-33.81%
Net Debt
-6.94M
ROCE
-30.48%
Diluted EPS TTM
-0.75

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -51.94M -89.94M -76.85M -36.98M -12.48M
Net income -51.66M -89.33M -76.85M -36.79M -12.48M
Selling general administrative 26.01M 29.52M 17.59M 8.95M 2.03M
Reconciled depreciation 0.20M 0.34M 0.33M 0.19M 0.05M
Ebit -52.02M -90.32M -78.89M -39.17M -11.31M
Ebitda -50.16M -89.97M -76.52M -36.98M -11.26M
Depreciation and amortization 1.85M 0.34M 2.38M 2.19M 0.05M
Non operating income net other 0.07M - - - -
Operating income -52.02M -90.32M -78.89M -39.17M -12.12M
Other operating expenses 51.19M 90.32M 78.89M 39.17M 12.12M
Interest expense 0.57M 0.37M 2.04M 2.19M 0.96M
Tax provision -0.28M - - - -
Interest income 1.07M 0.62M 2.04M 2.19M 0.81M
Net interest income 1.07M 0.62M 2.04M 2.19M -0.15M
Non recurring 0.82M - - - -
Income tax expense -0.28M -0.62M -2.04M -0.19M 0.36M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 51.19M 90.32M 78.89M 39.17M 12.12M
Total other income expense net 0.07M 0.37M 2.04M 2.19M -0.21M
Net income from continuing ops -51.66M -89.94M -76.85M -36.98M -12.48M
Net income applicable to common shares -51.66M -89.94M -76.85M -36.98M -12.48M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 180.20M 103.91M 133.23M 189.47M 124.37M
Intangible assets 63.67M 5.90M - - -
Other current assets 1.39M 0.28M 1.50M 0.69M 0.69M
Total liab 95.12M 3.32M 14.64M 17.20M 8.89M
Total stockholder equity 85.08M 100.59M 118.59M 172.26M 115.48M
Deferred long term liab - 0.25M - - -
Other current liab 7.47M 2.05M 0.18M 13.44M 5.82M
Common stock 0.04M 0.04M 0.03M 0.03M 0.03M
Capital stock 0.04M 0.04M 0.03M 0.03M 0.03M
Retained earnings -319.64M -288.26M -236.60M -146.65M -69.81M
Other liab - 0.25M - - -
Good will 17.62M - - - -
Other assets - - 0.19M 0.04M 0.22M
Cash 20.75M 44.58M 69.72M 66.84M 51.21M
Total current liabilities 9.57M 3.07M 14.22M 17.00M 8.89M
Current deferred revenue - - 8.39M - -
Net debt -6.94M -44.13M -68.56M -66.63M -51.21M
Short term debt 0.06M 0.45M 0.74M - -
Short long term debt total 13.81M 0.45M 1.16M 0.21M -
Other stockholder equity 401.64M 389.11M 355.23M 318.57M 60.83M
Property plant equipment - 0.39M 1.43M 1.10M 1.33M
Total current assets 77.44M 93.75M 111.67M 137.86M 106.06M
Long term investments 0.08M 3.58M 19.93M 50.46M 16.76M
Net tangible assets - 100.59M 118.59M 172.26M 115.48M
Short term investments 54.31M 45.60M 37.08M 66.98M 48.65M
Net receivables 0.99M 1.00M 1.13M - -
Long term debt 13.43M - - - -
Inventory - 2.29M - - -
Accounts payable 2.03M 0.57M 4.91M 3.56M 3.08M
Accumulated other comprehensive income 3.05M -0.29M -0.08M 0.31M 0.06M
Common stock total equity - 0.04M - - -
Retained earnings total equity - -288.26M - - -
Non currrent assets other 8.47M - 0.19M 0.04M 0.22M
Non current assets total 102.76M 10.16M 21.55M 51.60M 18.31M
Capital lease obligations 0.39M 0.45M 1.16M 0.21M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 7.47M 59.13M -52.38M -17.69M -46.54M
Change to liabilities -12.60M 1.36M 0.48M 2.58M -0.02M
Total cashflows from investing activities 18.00M 58.95M -52.43M -17.75M -46.75M
Net borrowings -0.05M -0.05M -0.03M -0.56M 0.25M
Total cash from financing activities 0.71M 6.81M 118.88M 77.37M 75.93M
Change to operating activities -3.89M -5.62M 9.75M -0.68M -0.37M
Net income -51.66M -89.94M -76.85M -36.98M -12.48M
Change in cash -25.14M 2.88M 15.63M 26.34M 17.48M
Begin period cash flow 69.72M 66.84M 51.21M 24.87M 7.39M
End period cash flow 44.58M 69.72M 66.84M 51.21M 24.87M
Total cash from operating activities -44.04M -62.93M -50.82M -33.28M -11.70M
Issuance of capital stock 0.61M 0.00M 117.63M 77.83M 75.69M
Depreciation 0.20M 0.34M 0.33M 0.19M 0.05M
Other cashflows from investing activities 10.66M - - - -
Sale purchase of stock 16.50M - - - -
Other cashflows from financing activities -16.36M 6.81M 1.28M 0.10M 75.93M
Change to netincome 16.62M 30.93M 15.47M 1.61M 0.43M
Capital expenditures 0.13M 0.18M 0.05M 0.06M 0.21M
Cash flows other operating 3.52M - - - -
Cash and cash equivalents changes -25.33M - - - -
Change in working capital -9.83M -4.26M 10.23M 1.90M -0.39M
Stock based compensation 16.62M 29.85M 14.47M 2.06M 0.15M
Other non cash items 0.91M 0.20M 0.37M 0.37M 1.11M
Free cash flow -44.17M -63.11M -50.87M -33.33M -11.91M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
QNCX
Quince Therapeutics, Inc.		 2.77
8.95%		 33.77 - - - 0.48 0.76
NVO
Novo Nordisk A/S		 -0.68
1.64%		 40.70 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.02
0.55%		 547.85 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -
-%		 916.06 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Quince Therapeutics, Inc.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

601 Gateway Blvd, South San Francisco, CA, United States, 94080

415 910 5717

https://www.quincetx.com

32

Name Title Year Born
Dr. Leslie J. Holsinger Ph.D. Consultant 1965
Dr. Dirk Thye M.D. CEO & Director 1970
Mr. Ted Monohon VP of Fin., Principal Financial Officer & Chief Accounting Officer 1966
Ms. Stacy Roughan VP of Corp. Communications & Investor Relations NA
Ms. Mary Ellen Sillivos VP of HR NA
Mr. Brendan Hannah M.B.A. Chief Bus. Officer NA
Dr. Karen L. Smith L.L.M, L.L.M., M.B.A., M.D., PH.D. Chief Medical Officer 1968
Dr. Stewart A. Low Ph.D. Head of Discovery NA
Mr. Brendan Hannah M.B.A. Principal Financial Officer, Principal Accounting Officer, Chief Business Officer & COO 1986
Dr. Charles S. Ryan J.D., Ph.D. President 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…